Efficacy of preexposure prophylaxis with monoclonal-antibody tixagevimab-cilgavimab against emerging SARS-CoV-2 resistant variants in patients with chronic lymphocytic leukemia.

MLA

Benjamini, Ohad, et al. “Efficacy of Preexposure Prophylaxis with Monoclonal-Antibody Tixagevimab-Cilgavimab against Emerging SARS-CoV-2 Resistant Variants in Patients with Chronic Lymphocytic Leukemia.” Acta Haematologica, Mar. 2024. EBSCOhost, https://doi.org/10.1159/000537690.

APA

Benjamini, O., Tadmor, T., Avigdor, A., Gershon, R., Kliker, L., Fares, F., Atari, N., Laevsky, I., Abd Elkader, B., Hod, T., Golan-Shany, O., Mandelboim, M., & Rahav, G. (2024). Efficacy of preexposure prophylaxis with monoclonal-antibody tixagevimab-cilgavimab against emerging SARS-CoV-2 resistant variants in patients with chronic lymphocytic leukemia. Acta Haematologica. https://doi.org/10.1159/000537690

Chicago

Benjamini, Ohad, Tamar Tadmor, Abraham Avigdor, Rotem Gershon, Limor Kliker, Florin Fares, Nofar Atari, et al. 2024. “Efficacy of Preexposure Prophylaxis with Monoclonal-Antibody Tixagevimab-Cilgavimab against Emerging SARS-CoV-2 Resistant Variants in Patients with Chronic Lymphocytic Leukemia.” Acta Haematologica, March. doi:10.1159/000537690.